Help NK cell therapy - Shenzhen Cell Valley and Enkesai reach a comprehensive strategic cooperation
From September 26 to 27, 2022, Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley Biomedicine Co., LTD., Professor Wang Jianxun, Chief scientist of Shenzhen Cell Valley Biomedicine Co., LTD., and Yang Bolui, Executive President and Feng Yaru, vice president of Guangdong Junhou Biomedicine Co., LTD., arrived at Enkesai. The company communicated and discussed with Mr. Tian Zhigang, chairman of the board, Professor Xiao Weihua, General manager, and some core technical team members on the development of comprehensive strategic cooperation.
Professor Shi Yuanyuan and his delegation visited the exhibition hall of the company, and Zhang Wenrui, Executive director of administrative operations of Enkesai Pharmaceuticals, introduced the development history, core management team, technology platform, product pipeline, and scientific research progress of Enkesai Pharmaceuticals. The two sides exchanged views on the source innovation of immune cell drugs.
Subsequently, the two sides held a symposium, Enkesai Pharmaceutical chairman Tian Zhigang Academician, CEO Professor Xiao Weihua, research and development Executive director Dr. Fang Fang, scientific executive director Dr. Zhang CAI, Gene editing director Dr. Hu Yuan, research and Development director Dr. Xie Siqi, Dr. Xiao Xinghui, Shenzhen Cell Valley Biomedicine Co., LTD. Chairman Professor Shi Yuanyuan, chief scientist Professor Wang Jianxun, Yang Bolui, Executive president of Guangdong Junhou Biomedicine Co., LTD., Feng Yaru, Vice President & Technical Director, and Wei Zheng, assistant chairman of the board, attended the symposium.
At the symposium, the two sides conducted in-depth exchanges and communication on research and development, technology and other issues, and reached an agreement on the optimal development and production of retroviral vectors under the comprehensive strategic partnership, communicated on the implementation route and steps of the cooperation between the two sides, and determined to synchronously start the early development cooperation. This cooperation provides a guarantee for the development of the gene modification pipeline of Enkesai drugs, and provides a strong impetus for Shenzhen Cell Valley to enhance the capability of the CDMO technology platform.
Professor Shi Yuanyuan and his delegation visited the exhibition hall of the company, and Zhang Wenrui, Executive director of administrative operations of Enkesai Pharmaceuticals, introduced the development history, core management team, technology platform, product pipeline, and scientific research progress of Enkesai Pharmaceuticals. The two sides exchanged views on the source innovation of immune cell drugs.
Subsequently, the two sides held a symposium, Enkesai Pharmaceutical chairman Tian Zhigang Academician, CEO Professor Xiao Weihua, research and development Executive director Dr. Fang Fang, scientific executive director Dr. Zhang CAI, Gene editing director Dr. Hu Yuan, research and Development director Dr. Xie Siqi, Dr. Xiao Xinghui, Shenzhen Cell Valley Biomedicine Co., LTD. Chairman Professor Shi Yuanyuan, chief scientist Professor Wang Jianxun, Yang Bolui, Executive president of Guangdong Junhou Biomedicine Co., LTD., Feng Yaru, Vice President & Technical Director, and Wei Zheng, assistant chairman of the board, attended the symposium.
At the symposium, the two sides conducted in-depth exchanges and communication on research and development, technology and other issues, and reached an agreement on the optimal development and production of retroviral vectors under the comprehensive strategic partnership, communicated on the implementation route and steps of the cooperation between the two sides, and determined to synchronously start the early development cooperation. This cooperation provides a guarantee for the development of the gene modification pipeline of Enkesai drugs, and provides a strong impetus for Shenzhen Cell Valley to enhance the capability of the CDMO technology platform.
